Genentech, Inc. (NYSE: DNA) announced a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the U.S. market. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE